NASDAQ · KROS
Healthcare · Biotechnology
$11.04
Down-$0.32 (-2.82%)
Updated Nov 2, 2026, 8:28 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KROS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
KROS closed at $11.04 after 20 trading sessions, down 4.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $11.32 | $11.49 | $10.975 | $11.04 | 120.16K |
| Oct 29, 2026 | $11.71 | $11.88 | $11.21 | $11.36 | 205.12K |
| Oct 28, 2026 | $11.34 | $11.79 | $11.20 | $11.61 | 183.22K |
| Oct 27, 2026 | $11.37 | $11.63 | $11.19 | $11.425 | 148.51K |
| Oct 26, 2026 | $11.30 | $11.51 | $11.2037 | $11.33 | 112.41K |
| Oct 23, 2026 | $11.28 | $11.34 | $10.92 | $11.28 | 120.9K |
| Oct 22, 2026 | $11.15 | $11.44 | $11.15 | $11.35 | 115.51K |
| Oct 21, 2026 | $11.40 | $11.68 | $11.11 | $11.18 | 178.14K |
| Oct 20, 2026 | $11.04 | $11.665 | $11.04 | $11.40 | 153.38K |
| Oct 19, 2026 | $10.68 | $11.15 | $10.66 | $11.06 | 210.65K |
| Oct 16, 2026 | $11.11 | $11.13 | $10.63 | $10.66 | 169.64K |
| Oct 15, 2026 | $11.13 | $11.40 | $10.98 | $11.10 | 96.67K |
| Oct 14, 2026 | $11.07 | $11.30 | $10.92 | $11.05 | 159.14K |
| Oct 13, 2026 | $11.65 | $11.69 | $11.19 | $11.23 | 144.5K |
| Oct 12, 2026 | $11.77 | $12.08 | $11.583 | $11.61 | 223.68K |
| Oct 9, 2026 | $11.58 | $12.26 | $11.49 | $11.95 | 194.39K |
| Oct 8, 2026 | $11.13 | $11.76 | $10.99 | $11.64 | 245.66K |
| Oct 7, 2026 | $10.81 | $11.34 | $10.81 | $11.21 | 195.96K |
| Oct 6, 2026 | $11.56 | $11.63 | $10.95 | $11.01 | 185.32K |
| Oct 5, 2026 | $11.38 | $11.56 | $11.07 | $11.52 | 132.41K |
The latest Smart Investors Daily articles mentioning KROS.
Company
Market Activity
Research & News
KROS research
Company profile and research snapshot.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Leerink Partners | Outperform | — |
| Aug 4, 2026 | Wells Fargo | Overweight | — |
| Mar 5, 2026 | Wells Fargo | Overweight | — |
| Nov 28, 2025 | B of A Securities | Neutral | — |
| Nov 12, 2025 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Keros Therapeutics (NASDAQ:KROS) is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under Takeda, Chief Executive Officer Jasbir Seehra
Yahoo · Sep 29, 2026
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of
Yahoo · Sep 28, 2026
Initial data expected in the first half of 2027LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of ri
Benzinga · Sep 28, 2026
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KROS.
